Evonik Expanding Global Isophorone and Isophorone Diamine Capacities
News Nov 15, 2013
Evonik Industries is significantly expanding its global isophorone (IP) and isophorone diamine (IPD) capacities by funding an investment of more than €100 million in Shanghai, China.
“We're investing in China, because we are committed to the growth region Asia. As a world leader in isophorone-based products, we will continue to further consolidate and expand our position in this chemistry," says Dr. Ulrich Küsthardt, President of Evonik’s Coating & Additives Business Unit.
With the Group’s expansion strategy it aims to support the growth ambitions of key customers in Asia and around the world. Proximity to consumers in this growing market will translate into improved local service, shorter lead times, and faster responses to changes in demand. “Our aim in building the plants in Shanghai— at the company’s existing multi-user site—is to supply our Asian customers with the same high-quality products they are used to from our plants in Europe and the USA, now from a plant in the region," says Gerd Brand, Senior Vice President and Head of Crosslinkers Business Line.
Evonik has proven expertise in the manufacturing of products based on isophorone, backed up by fifty years of experience. The Group is a global market leader in isophorone chemistry with production facilities in Herne, Marl (Germany), Mobile, Alabama (USA) and Antwerp (Belgium). Its products are known worldwide under the brand names of VESTAMIN®, VESTANAT®, VESTAGON® and VESTASOL®.
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019